MX2009013565A - Derivados de azapeptidos. - Google Patents

Derivados de azapeptidos.

Info

Publication number
MX2009013565A
MX2009013565A MX2009013565A MX2009013565A MX2009013565A MX 2009013565 A MX2009013565 A MX 2009013565A MX 2009013565 A MX2009013565 A MX 2009013565A MX 2009013565 A MX2009013565 A MX 2009013565A MX 2009013565 A MX2009013565 A MX 2009013565A
Authority
MX
Mexico
Prior art keywords
compounds
relates
hiv protease
novel
derivatives
Prior art date
Application number
MX2009013565A
Other languages
English (en)
Inventor
Roger D Tung
Scott L Haberson
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2009013565A publication Critical patent/MX2009013565A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings

Abstract

Esta invención se refiere a nuevos compuestos que son azapéptidos y a sales farmacéuticamente aceptables de los mismos. Más específicamente, la invención se refiere a nuevos compuestos de azapéptidos que son derivados del inhibidor de la proteasa del VIH sulfato de atazanavir. Esta invención también proporciona composiciones sin pirógenos que comprenden uno o más compuestos de la invención y un soporte y el uso de los compuestos y composiciones descritas para tratar enfermedades y afecciones que se tratan mediante la administración de inhibidores de la proteasa del VIH. La invención también se refiere al uso de uno o más de los compuestos descritos como reactivos en estudios analíticos que implican atazanavir.
MX2009013565A 2007-06-12 2008-06-12 Derivados de azapeptidos. MX2009013565A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93420107P 2007-06-12 2007-06-12
US6762708P 2008-02-29 2008-02-29
PCT/US2008/007331 WO2008156632A1 (en) 2007-06-12 2008-06-12 Azapeptide derivatives

Publications (1)

Publication Number Publication Date
MX2009013565A true MX2009013565A (es) 2010-06-02

Family

ID=39730784

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013565A MX2009013565A (es) 2007-06-12 2008-06-12 Derivados de azapeptidos.

Country Status (26)

Country Link
US (4) US20090036357A1 (es)
EP (3) EP2003120B9 (es)
JP (1) JP2010529196A (es)
KR (2) KR101185899B1 (es)
CN (2) CN101711237B (es)
AR (1) AR066972A1 (es)
AT (2) ATE536343T1 (es)
AU (1) AU2008267048C1 (es)
BR (2) BRPI0823520A2 (es)
CA (1) CA2692028C (es)
CO (1) CO6241121A2 (es)
CY (1) CY1109766T1 (es)
DE (1) DE602008000255D1 (es)
DK (1) DK2003120T3 (es)
ES (3) ES2356334T3 (es)
HK (2) HK1127345A1 (es)
HR (1) HRP20100065T1 (es)
MX (1) MX2009013565A (es)
PL (1) PL2003120T3 (es)
PT (1) PT2003120E (es)
RS (1) RS51226B (es)
RU (2) RU2448958C2 (es)
SI (1) SI2003120T1 (es)
TW (1) TW200908970A (es)
WO (1) WO2008156632A1 (es)
ZA (1) ZA200909079B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200835693A (en) * 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
AU2008267048C1 (en) 2007-06-12 2013-01-17 Concert Pharmaceuticals, Inc. Azapeptide derivatives
ES2574988T3 (es) * 2008-10-06 2016-06-23 Yissum Research Development Company Of The Herbrew University Of Jerusalem Ltd. Péptidos derivados de estimulantes de la VIH-1 integrasa que interfieren con la proteína Rev-integrasa
WO2010132663A1 (en) * 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors
WO2010135424A1 (en) * 2009-05-19 2010-11-25 Glaxosmithkline Llc Chemical compounds
KR101798430B1 (ko) 2009-12-21 2017-11-16 얀센 사이언시즈 아일랜드 유씨 활성 화합물의 서방출을 위한 분해 및 제거가능한 임플란트
WO2011080562A1 (en) 2009-12-29 2011-07-07 Hetero Research Foundation Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals
ME03375B (me) 2011-06-20 2020-01-20 H Lundbeck As Deuterizovani 1-piperazin0-3-fenil indani za tretiranje šizofrenije
CN106543073A (zh) * 2015-09-17 2017-03-29 宁波杰尔盛化工有限公司 2-[4-（2-吡啶基）苄基]-肼羧酸叔丁酯的制备方法
CN108367008B (zh) * 2015-12-02 2021-04-30 默沙东公司 包含多拉韦林、富马酸替诺福韦二吡呋酯和拉米夫定的药物组合物
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
MA53010A (fr) 2018-06-29 2021-05-05 Incyte Corp Formulations d'un inhibiteur de axl/mer
TWI829205B (zh) 2018-07-30 2024-01-11 美商基利科學股份有限公司 抗hiv化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1314875C (en) 1985-05-15 1993-03-23 George Walter Koszalka Therapeutic nucleosides
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5539122A (en) 1989-05-23 1996-07-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
DK0727419T3 (da) 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
TW409125B (en) * 1996-04-22 2000-10-21 Novartis Ag Antivirally active heterocyclic azahexane derivatives
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
WO1997046514A1 (en) 1996-05-31 1997-12-11 Novartis Ag Process for the preparation of hydrazine derivatives useful as intermediates for the preparation of peptide analogues
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9914821D0 (en) 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
CZ20033211A3 (cs) 2001-05-03 2004-09-15 F. Hoffmann-La Roche Ag Farmaceutická léková forma amorfního nelfinavir mesylátu
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
RU2316341C2 (ru) 2001-08-31 2008-02-10 Бристол-Маерс Сквибб Компани Применение атазанавира в терапии вич-инфекции
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
AU2004273773B2 (en) 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20050148523A1 (en) 2003-12-15 2005-07-07 Colonno Richard J. Method of treating HIV infection in atazanavir-resistant patients using a combination of atazanavir and another protease inhibitor
US7829720B2 (en) * 2004-05-04 2010-11-09 Bristol-Myers Squibb Company Process for preparing atazanavir bisulfate and novel forms
EP2336138A3 (en) * 2004-07-06 2011-11-16 Abbott Laboratories Prodrugs of HIV protease inhibitors
AU2005292339A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
CN101068916A (zh) 2004-12-03 2007-11-07 默克公司 阿扎那韦用于改良通过ugt1a1代谢的药物的药物动力学的用途
CA2624179A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
WO2008030382A1 (en) 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
AU2008267048C1 (en) 2007-06-12 2013-01-17 Concert Pharmaceuticals, Inc. Azapeptide derivatives
US20090076097A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched atazanavir
WO2010132663A1 (en) 2009-05-13 2010-11-18 Concert Pharmaceticals, Inc. Pegylated azapeptide derivatives as hiv protease inhibitors

Also Published As

Publication number Publication date
TW200908970A (en) 2009-03-01
AR066972A1 (es) 2009-09-23
EP2116532A1 (en) 2009-11-11
CY1109766T1 (el) 2014-09-10
PT2003120E (pt) 2010-02-11
EP2322509B1 (en) 2012-08-22
EP2003120B1 (en) 2009-11-04
ES2356334T3 (es) 2011-04-07
ATE536343T1 (de) 2011-12-15
PL2003120T3 (pl) 2010-04-30
US8158805B2 (en) 2012-04-17
US20090036357A1 (en) 2009-02-05
AU2008267048A1 (en) 2008-12-24
CN102424668A (zh) 2012-04-25
RU2012101881A (ru) 2013-07-27
KR101185899B1 (ko) 2012-09-27
KR20120029480A (ko) 2012-03-26
ATE447554T1 (de) 2009-11-15
US20110009355A1 (en) 2011-01-13
RU2010100821A (ru) 2011-07-20
SI2003120T1 (sl) 2010-03-31
AU2008267048B2 (en) 2012-05-31
EP2322509A1 (en) 2011-05-18
US20120165288A1 (en) 2012-06-28
EP2003120B9 (en) 2010-06-02
CA2692028A1 (en) 2008-12-24
WO2008156632A1 (en) 2008-12-24
CA2692028C (en) 2013-06-04
RU2448958C2 (ru) 2012-04-27
HK1136576A1 (en) 2010-07-02
EP2003120A1 (en) 2008-12-17
BRPI0813911A2 (pt) 2012-02-22
CN101711237B (zh) 2013-08-07
JP2010529196A (ja) 2010-08-26
DK2003120T3 (da) 2010-03-15
CO6241121A2 (es) 2011-01-20
CN101711237A (zh) 2010-05-19
HRP20100065T1 (hr) 2010-03-31
KR20100020033A (ko) 2010-02-19
ES2395137T3 (es) 2013-02-08
US20130041156A1 (en) 2013-02-14
BRPI0823520A2 (pt) 2013-12-17
US8258309B2 (en) 2012-09-04
HK1127345A1 (en) 2009-09-25
ZA200909079B (en) 2011-05-25
DE602008000255D1 (de) 2009-12-17
AU2008267048C1 (en) 2013-01-17
RS51226B (sr) 2010-12-31
ES2394952T3 (es) 2013-02-07
EP2116532B1 (en) 2011-12-07

Similar Documents

Publication Publication Date Title
MX2009013565A (es) Derivados de azapeptidos.
PH12014501134A1 (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
TN2014000079A1 (en) Selective and reversible inhibitors of ubiquitin specific protease 7
TW200744586A (en) Therapeutic compounds
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
BRPI0415960A (pt) composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, uso de um composto,e, método para produzir um composto
MX336381B (es) Boronatos como inhibidores de arginasa.
IN2014MN01183A (es)
UA104137C2 (ru) Пиридилсодержащие ингибиторы передачи сигнала через белок hedgehog
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
MX2013005543A (es) Metodo para el tratamiento de nefropatia inducida por contraste.
AU2012204982A8 (en) 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
WO2007059154A3 (en) Treatment of cancers with acquired resistance to kit inhibitors
ZA200806778B (en) N-Hydroxyacrylamide compounds
TW200726758A (en) New pyridine analogues
UA97806C2 (ru) Бензиламины, способ их получения и их применения в качестве противовоспалительных средств
DK1885187T3 (da) Fremgangsmåde til behandling af lægemiddelresistent cancer
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TNSN06260A1 (en) Process for the preparation of tryptase inhibitors
WO2010019701A3 (en) Diaryl urea derivatives
EA200701852A1 (ru) Производные аминокислот
TW200833335A (en) New pyridine analogues
WO2009148600A8 (en) Deuterated lysine-based compounds

Legal Events

Date Code Title Description
FG Grant or registration